Surface Oncology, Inc.
Surface Oncology, Inc. (SURF): 5 pipeline candidates · ~9 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
8.5 months
D/E 0.34 · 0% dilution
Lead: Phase 1
5 candidates
N/A
N/A
A transparent, data-derived signal for Surface Oncology, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$14.8M
Quarterly Burn
$19.6M
Runway
8.5 mo
Revenue
$0
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| gsk4381562 | Phase 1 |
| nzv930 | Phase 1 |
| srf114 | Preclinical |
| srf388 | Phase 1 |
| srf617 | Phase 1 |
Frequently asked questions
How many drug candidates are in Surface Oncology, Inc.'s pipeline?
Surface Oncology, Inc. (SURF) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Surface Oncology, Inc.'s lead drug candidate?
Surface Oncology, Inc.'s most advanced tracked candidate is gsk4381562 (Phase 1) for Cancer.
What is Surface Oncology, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Surface Oncology, Inc. has approximately 8.5 months of cash runway.
Who is the CEO of Surface Oncology, Inc.?
Robert W. Ross, M.D. is the chief executive officer of Surface Oncology, Inc. (SURF).
Get the full picture on Surface Oncology, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.